Neurocrine Biosciences (NBIX) Receivables (2016 - 2021)
Historic Receivables for Neurocrine Biosciences (NBIX) over the last 12 years, with Q3 2021 value amounting to $166.6 million.
- Neurocrine Biosciences' Receivables rose 386.53% to $166.6 million in Q3 2021 from the same period last year, while for Sep 2021 it was $166.6 million, marking a year-over-year increase of 386.53%. This contributed to the annual value of $160.8 million for FY2020, which is 2701.42% up from last year.
- According to the latest figures from Q3 2021, Neurocrine Biosciences' Receivables is $166.6 million, which was up 386.53% from $161.2 million recorded in Q2 2021.
- Neurocrine Biosciences' Receivables' 5-year high stood at $166.6 million during Q3 2021, with a 5-year trough of $6.1 million in Q2 2017.
- In the last 5 years, Neurocrine Biosciences' Receivables had a median value of $105.6 million in 2019 and averaged $98.9 million.
- As far as peak fluctuations go, Neurocrine Biosciences' Receivables surged by 60210.73% in 2018, and later crashed by 150.03% in 2021.
- Quarter analysis of 5 years shows Neurocrine Biosciences' Receivables stood at $31.1 million in 2017, then soared by 84.43% to $57.4 million in 2018, then soared by 120.53% to $126.6 million in 2019, then rose by 27.01% to $160.8 million in 2020, then grew by 3.61% to $166.6 million in 2021.
- Its Receivables was $166.6 million in Q3 2021, compared to $161.2 million in Q2 2021 and $151.0 million in Q1 2021.